+1-650-457-5617meetings@svicenter.com
+1-650-457-5617
meetings@svicenter.com

Visit Carmot Therapeutics

Developer of drugs designed to unlock novel therapeutic target space not currently accessible to conventional small molecule technologies

Select Meeting Details
Carmot Therapeutics

Extra services

We will confirm the details of your meeting after it is accepted by the host company

Developer of drugs designed to unlock novel therapeutic target space not currently accessible to conventional small molecule technologies. The company's drugs are made with proprietary Chemotype Evolution technology that helps in the rapid identification of novel drugs through an evolutionary lead-identification paradigm, enabling patients to cure metabolic diseases, cancer and inflammation.

Year Founded
2010
Employees
12
General Information
  • Website

    http://carmot.us

  • Business Status

    Pre-Clinical Trials

  • Ownership Status

    Privately Held (backing)

  • Financing Status

    Venture Capital-Backed

Carmot Therapeutics's Verticals
Carmot Therapeutics Primary Industry Sector / Group / Code
Carmot Therapeutics Status

The company raised $15 million of Series B venture funding in a deal co-led by Horizons Ventures and The Column Group on January 17, 2018, putting the pre-money valuation at $47.2 million. Jerome Dahan and other undisclosed investors also participated in the round. The company intends to use the funds to support development of their lead type 2 diabetes drug through early clinical proof of concept and expansion of their efforts targeting de-ubiquitinating enzymes.

Carmot Therapeutics Metrics
Majestic Referring Domains
Headquarters
Get Directions
  • HQ Address Line 1
    740 Heinz Avenue
  • HQ City
    Berkeley
  • HQ State/Province
    California
  • HQ Post Code
    94710
  • HQ Country
    United States
mood_bad
  • No comments yet.
    • chat
    Add a review

    Leave a Reply ·

    mood_bad
  • Feed is empty.

    • You May Also Be Interested In